"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","characteristics_ch1.6","characteristics_ch1.7","characteristics_ch1.8","characteristics_ch1.9","characteristics_ch1.10","characteristics_ch1.11","characteristics_ch1.12","characteristics_ch1.13","characteristics_ch1.14","characteristics_ch1.15","characteristics_ch1.16","characteristics_ch1.17","characteristics_ch1.18","characteristics_ch1.19","characteristics_ch1.20","characteristics_ch1.21","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","source_name_ch2","organism_ch2","characteristics_ch2","molecule_ch2","extract_protocol_ch2","label_ch2","label_protocol_ch2","taxid_ch2","hyb_protocol","scan_protocol","scan_protocol.1","description","data_processing","platform_id","contact_name","contact_laboratory","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count"
"GSM302996","Patient 001 with adenocarcinoma","GSM302996","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD001","Position in Figure 1 (L to R): 90","Age: 71","Sex: M","Histology: AD","Smoking (BI): 1020","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 1326","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 68","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM302nnn/GSM302996/GSM302996.txt.gz","21619"
"GSM302997","Patient 002 with adenocarcinoma","GSM302997","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD002","Position in Figure 1 (L to R): 71","Age: 49","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 3275","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 54","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM302nnn/GSM302997/GSM302997.txt.gz","21619"
"GSM302998","Patient 003 with adenocarcinoma","GSM302998","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD003","Position in Figure 1 (L to R): 96","Age: 51","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 1687","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 65","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM302nnn/GSM302998/GSM302998.txt.gz","21619"
"GSM302999","Patient 004 with adenocarcinoma","GSM302999","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD004","Position in Figure 1 (L to R): 119","Age: 51","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N1M0","pStage: IIA","Status: Alive","Survival (days): 3214","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 90","Expression profile-based classification: TRU-b","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM302nnn/GSM302999/GSM302999.txt.gz","21619"
"GSM303000","Patient 005 with adenocarcinoma","GSM303000","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD005","Position in Figure 1 (L to R): 56","Age: 67","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N2M0","pStage: IIIA","Status: Dead","Survival (days): 1200","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 64","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303000/GSM303000.txt.gz","21619"
"GSM303001","Patient 006 with adenocarcinoma","GSM303001","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD006","Position in Figure 1 (L to R): 95","Age: 66","Sex: M","Histology: AD","Smoking (BI): 100","pTNM: T3N1M0","pStage: IIIA","Status: Dead","Survival (days): 223","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 69","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Positive","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303001/GSM303001.txt.gz","21619"
"GSM303002","Patient 007 with adenocarcinoma","GSM303002","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD007","Position in Figure 1 (L to R): 73","Age: 71","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 3245","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 53","Expression profile-based classification: TRU-a","Invasion: Definite but focal","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303002/GSM303002.txt.gz","21619"
"GSM303003","Patient 008 with adenocarcinoma","GSM303003","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD008","Position in Figure 1 (L to R): 75","Age: 62","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T4N0M0","pStage: IIIB","Status: Alive","Survival (days): 3274","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Mut","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 56","Expression profile-based classification: TRU-a","Invasion: Definite but focal","Necrosis: Negative","Grade: Well","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303003/GSM303003.txt.gz","21619"
"GSM303004","Patient 009 with adenocarcinoma","GSM303004","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD009","Position in Figure 1 (L to R): 85","Age: 47","Sex: F","Histology: AD","Smoking (BI): 120","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 511","Evidence of relapse: Y","Site of relapse: Liver, adrenal","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 59","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303004/GSM303004.txt.gz","21619"
"GSM303005","Patient 010 with adenocarcinoma","GSM303005","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD010","Position in Figure 1 (L to R): 72","Age: 60","Sex: F","Histology: AD","Smoking (BI): 150","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 3245","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 49","Expression profile-based classification: TRU-a","Invasion: Not obvious","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303005/GSM303005.txt.gz","21619"
"GSM303006","Patient 011 with adenocarcinoma","GSM303006","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD011","Position in Figure 1 (L to R): 142","Age: 64","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 3295","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 73","Expression profile-based classification: TRU-b","Invasion: Definite but focal","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303006/GSM303006.txt.gz","21619"
"GSM303007","Patient 012 with adenocarcinoma","GSM303007","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD012","Position in Figure 1 (L to R): 102","Age: 57","Sex: M","Histology: AD","Smoking (BI): 1110","pTNM: T2N2M0","pStage: IIIA","Status: Alive","Survival (days): 3260","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 12","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Focal","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303007/GSM303007.txt.gz","21619"
"GSM303008","Patient 013 with adenocarcinoma","GSM303008","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD013","Position in Figure 1 (L to R): 117","Age: 55","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T3N0M0","pStage: IIB","Status: Dead","Survival (days): 1855","Evidence of relapse: Y","Site of relapse: Liver","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 89","Expression profile-based classification: TRU-b","Invasion: Definite","Necrosis: Positive","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303008/GSM303008.txt.gz","21619"
"GSM303009","Patient 014 with adenocarcinoma","GSM303009","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD014","Position in Figure 1 (L to R): 118","Age: 74","Sex: M","Histology: AD","Smoking (BI): 810","pTNM: T1N2M0","pStage: IIIA","Status: Dead","Survival (days): 694","Evidence of relapse: Y","Site of relapse: LN (mediastinal)","EGFR status: Wt","K-ras Status: Mut","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 5","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303009/GSM303009.txt.gz","21619"
"GSM303010","Patient 015 with adenocarcinoma","GSM303010","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD015","Position in Figure 1 (L to R): 78","Age: 61","Sex: M","Histology: AD","Smoking (BI): 1230","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 3246","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 62","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303010/GSM303010.txt.gz","21619"
"GSM303011","Patient 016 with adenocarcinoma","GSM303011","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD016","Position in Figure 1 (L to R): 57","Age: 67","Sex: F","Histology: AD","Smoking (BI): 200","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 3169","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 57","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Positive","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303011/GSM303011.txt.gz","21619"
"GSM303012","Patient 017 with adenocarcinoma","GSM303012","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD017","Position in Figure 1 (L to R): 59","Age: 63","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 3161","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 43","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303012/GSM303012.txt.gz","21619"
"GSM303013","Patient 018 with adenocarcinoma","GSM303013","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD018","Position in Figure 1 (L to R): 65","Age: 59","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 1030","Evidence of relapse: Y","Site of relapse: Local rec.","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 44","Expression profile-based classification: TRU-a","Invasion: Definite but focal","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303013/GSM303013.txt.gz","21619"
"GSM303014","Patient 019 with adenocarcinoma","GSM303014","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD019","Position in Figure 1 (L to R): 92","Age: 66","Sex: M","Histology: AD","Smoking (BI): 1040","pTNM: T1N2M0","pStage: IIIA","Status: Dead","Survival (days): 2102","Evidence of relapse: Y","Site of relapse: LN (mediastinal)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 67","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Focal","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303014/GSM303014.txt.gz","21619"
"GSM303015","Patient 020 with adenocarcinoma","GSM303015","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD020","Position in Figure 1 (L to R): 133","Age: 68","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N2M0","pStage: IIIA","Status: Alive","Survival (days): 3057","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 85","Expression profile-based classification: TRU-b","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303015/GSM303015.txt.gz","21619"
"GSM303016","Patient 021 with adenocarcinoma","GSM303016","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD021","Position in Figure 1 (L to R): 77","Age: 64","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 3182","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 61","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303016/GSM303016.txt.gz","21619"
"GSM303017","Patient 022 with adenocarcinoma","GSM303017","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD022","Position in Figure 1 (L to R): 66","Age: 70","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 3009","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 79","Expression profile-based classification: TRU-b","Invasion: Definite but focal","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303017/GSM303017.txt.gz","21619"
"GSM303018","Patient 023 with adenocarcinoma","GSM303018","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD023","Position in Figure 1 (L to R): 62","Age: 43","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 3004","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 71","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303018/GSM303018.txt.gz","21619"
"GSM303019","Patient 024 with adenocarcinoma","GSM303019","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD024","Position in Figure 1 (L to R): 70","Age: 73","Sex: M","Histology: AD","Smoking (BI): 430","pTNM: T1N2M0","pStage: IIIA","Status: Alive","Survival (days): 3170","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 58","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303019/GSM303019.txt.gz","21619"
"GSM303020","Patient 025 with adenocarcinoma","GSM303020","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD025","Position in Figure 1 (L to R): 149","Age: 72","Sex: M","Histology: AD","Smoking (BI): 636","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2974","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 32","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303020/GSM303020.txt.gz","21619"
"GSM303021","Patient 026 with adenocarcinoma","GSM303021","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD026","Position in Figure 1 (L to R): 68","Age: 56","Sex: M","Histology: AD","Smoking (BI): 1200","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2879","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 81","Expression profile-based classification: TRU-b","Invasion: Negative","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303021/GSM303021.txt.gz","21619"
"GSM303022","Patient 027 with adenocarcinoma","GSM303022","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD027","Position in Figure 1 (L to R): 63","Age: 75","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T3N0M0","pStage: IIB","Status: Dead","Survival (days): 1271","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 63","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303022/GSM303022.txt.gz","21619"
"GSM303023","Patient 028 with adenocarcinoma","GSM303023","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD028","Position in Figure 1 (L to R): 69","Age: 61","Sex: M","Histology: AD","Smoking (BI): 150","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2873","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 78","Expression profile-based classification: TRU-b","Invasion: Not obvious","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303023/GSM303023.txt.gz","21619"
"GSM303024","Patient 029 with adenocarcinoma","GSM303024","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD029","Position in Figure 1 (L to R): 100","Age: 62","Sex: M","Histology: AD","Smoking (BI): 1600","pTNM: T2N1M0","pStage: IIB","Status: Alive","Survival (days): 2979","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 1","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303024/GSM303024.txt.gz","21619"
"GSM303025","Patient 030 with adenocarcinoma","GSM303025","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD030","Position in Figure 1 (L to R): 91","Age: 61","Sex: M","Histology: AD","Smoking (BI): 1140","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2905","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Mut","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 66","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303025/GSM303025.txt.gz","21619"
"GSM303026","Patient 031 with adenocarcinoma","GSM303026","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD031","Position in Figure 1 (L to R): 137","Age: 32","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T4N2M0","pStage: IIIB","Status: Dead","Survival (days): 2885","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment: Y","Position in Figure 2 (L to R): 75","Expression profile-based classification: TRU-b","Invasion: Not obvious","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303026/GSM303026.txt.gz","21619"
"GSM303027","Patient 032 with adenocarcinoma","GSM303027","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD032","Position in Figure 1 (L to R): 122","Age: 53","Sex: M","Histology: AD","Smoking (BI): 1980","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2701","Evidence of relapse: Y","Site of relapse: Bone","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 2","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303027/GSM303027.txt.gz","21619"
"GSM303028","Patient 033 with adenocarcinoma","GSM303028","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD033","Position in Figure 1 (L to R): 74","Age: 66","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T4N0M0","pStage: IIIB","Status: Dead","Survival (days): 896","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Mut","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 55","Expression profile-based classification: TRU-a","Invasion: Definite but focal","Necrosis: Negative","Grade: Well","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303028/GSM303028.txt.gz","21619"
"GSM303029","Patient 034 with adenocarcinoma","GSM303029","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD034","Position in Figure 1 (L to R): 51","Age: 55","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T3N2M0","pStage: IIIA","Status: Alive","Survival (days): 2910","Evidence of relapse: Y","Site of relapse: LN (neck)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 7","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303029/GSM303029.txt.gz","21619"
"GSM303030","Patient 035 with adenocarcinoma","GSM303030","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD035","Position in Figure 1 (L to R): 61","Age: 62","Sex: M","Histology: AD","Smoking (BI): 400","pTNM: T3N0M0","pStage: IIB","Status: Alive","Survival (days): 2813","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 70","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Well","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303030/GSM303030.txt.gz","21619"
"GSM303031","Patient 036 with adenocarcinoma","GSM303031","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD036","Position in Figure 1 (L to R): 67","Age: 64","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2749","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 80","Expression profile-based classification: TRU-b","Invasion: Not obvious","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303031/GSM303031.txt.gz","21619"
"GSM303032","Patient 037 with adenocarcinoma","GSM303032","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD037","Position in Figure 1 (L to R): 94","Age: 63","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2932","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment: Y","Position in Figure 2 (L to R): 41","Expression profile-based classification: TRU-a","Invasion: Definite but focal","Necrosis: Negative","Grade: Well","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303032/GSM303032.txt.gz","21619"
"GSM303033","Patient 038 with adenocarcinoma","GSM303033","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD038","Position in Figure 1 (L to R): 83","Age: 69","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 1389","Evidence of relapse: Y","Site of relapse: Local rec.","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 46","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303033/GSM303033.txt.gz","21619"
"GSM303034","Patient 039 with adenocarcinoma","GSM303034","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD039","Position in Figure 1 (L to R): 76","Age: 52","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2796","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 51","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303034/GSM303034.txt.gz","21619"
"GSM303035","Patient 040 with adenocarcinoma","GSM303035","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD040","Position in Figure 1 (L to R): 82","Age: 52","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 361","Evidence of relapse: Y","Site of relapse: Bone","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 45","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303035/GSM303035.txt.gz","21619"
"GSM303036","Patient 041 with adenocarcinoma","GSM303036","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD041","Position in Figure 1 (L to R): 58","Age: 62","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 397","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 42","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303036/GSM303036.txt.gz","21619"
"GSM303037","Patient 042 with adenocarcinoma","GSM303037","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD042","Position in Figure 1 (L to R): 81","Age: 62","Sex: M","Histology: AD","Smoking (BI): 840","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2506","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 48","Expression profile-based classification: TRU-a","Invasion: Definite but focal","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303037/GSM303037.txt.gz","21619"
"GSM303038","Patient 043 with adenocarcinoma","GSM303038","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD043","Position in Figure 1 (L to R): 98","Age: 67","Sex: M","Histology: AD","Smoking (BI): 820","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2426","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 11","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303038/GSM303038.txt.gz","21619"
"GSM303039","Patient 044 with adenocarcinoma","GSM303039","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD044","Position in Figure 1 (L to R): 106","Age: 63","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N2M0","pStage: IIIA","Status: Dead","Survival (days): 2193","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment: Y","Position in Figure 2 (L to R): 72","Expression profile-based classification: TRU-b","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303039/GSM303039.txt.gz","21619"
"GSM303040","Patient 045 with adenocarcinoma","GSM303040","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD045","Position in Figure 1 (L to R): 104","Age: 49","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2797","Evidence of relapse: Y","Site of relapse: Adrenal","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 37","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303040/GSM303040.txt.gz","21619"
"GSM303041","Patient 046 with adenocarcinoma","GSM303041","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD046","Position in Figure 1 (L to R): 138","Age: 59","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N1M0","pStage: IIB","Status: Alive","Survival (days): 2355","Evidence of relapse: Y","Site of relapse: Bone","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 84","Expression profile-based classification: TRU-b","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303041/GSM303041.txt.gz","21619"
"GSM303042","Patient 047 with adenocarcinoma","GSM303042","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD047","Position in Figure 1 (L to R): 140","Age: 46","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T1N1M0","pStage: IIA","Status: Alive","Survival (days): 2729","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 82","Expression profile-based classification: TRU-b","Invasion: Not obvious","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303042/GSM303042.txt.gz","21619"
"GSM303043","Patient 048 with adenocarcinoma","GSM303043","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD048","Position in Figure 1 (L to R): 139","Age: 61","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2702","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 83","Expression profile-based classification: TRU-b","Invasion: Definite but focal","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303043/GSM303043.txt.gz","21619"
"GSM303044","Patient 049 with adenocarcinoma","GSM303044","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD049","Position in Figure 1 (L to R): 103","Age: 35","Sex: F","Histology: AD","Smoking (BI): 20","pTNM: T4N2M0","pStage: IIIB","Status: Dead","Survival (days): 636","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 36","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303044/GSM303044.txt.gz","21619"
"GSM303045","Patient 050 with adenocarcinoma","GSM303045","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD050","Position in Figure 1 (L to R): 112","Age: 76","Sex: M","Histology: AD","Smoking (BI): 1620","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 828","Evidence of relapse: Unknown","Site of relapse:","EGFR status: Wt","K-ras Status: Mut","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 20","Expression profile-based classification: Non-TRU","Invasion: Definite but focal","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303045/GSM303045.txt.gz","21619"
"GSM303046","Patient 051 with adenocarcinoma","GSM303046","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD051","Position in Figure 1 (L to R): 89","Age: 76","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2702","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 60","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303046/GSM303046.txt.gz","21619"
"GSM303047","Patient 052 with adenocarcinoma","GSM303047","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD052","Position in Figure 1 (L to R): 131","Age: 84","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2456","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 6","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303047/GSM303047.txt.gz","21619"
"GSM303048","Patient 053 with adenocarcinoma","GSM303048","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD053","Position in Figure 1 (L to R): 114","Age: 64","Sex: M","Histology: AD","Smoking (BI): 1540","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 784","Evidence of relapse: Y","Site of relapse: LN (neck)","EGFR status: Wt","K-ras Status: Mut","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 19","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303048/GSM303048.txt.gz","21619"
"GSM303049","Patient 054 with adenocarcinoma","GSM303049","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD054","Position in Figure 1 (L to R): 113","Age: 53","Sex: F","Histology: AD","Smoking (BI): 835","pTNM: T4N2M0","pStage: IIIB","Status: Dead","Survival (days): 596","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 18","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303049/GSM303049.txt.gz","21619"
"GSM303050","Patient 055 with adenocarcinoma","GSM303050","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD055","Position in Figure 1 (L to R): 129","Age: 53","Sex: F","Histology: AD","Smoking (BI): 120","pTNM: T1N2M0","pStage: IIIA","Status: Alive","Survival (days): 2520","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 31","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303050/GSM303050.txt.gz","21619"
"GSM303051","Patient 056 with adenocarcinoma","GSM303051","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD056","Position in Figure 1 (L to R): 136","Age: 62","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 2347","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment: Y","Position in Figure 2 (L to R): 74","Expression profile-based classification: TRU-b","Invasion: Not obvious","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303051/GSM303051.txt.gz","21619"
"GSM303052","Patient 057 with adenocarcinoma","GSM303052","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD057","Position in Figure 1 (L to R): 127","Age: 73","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 1880","Evidence of relapse: Y","Site of relapse: Local rec.","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment: Y","Position in Figure 2 (L to R): 28","Expression profile-based classification: Non-TRU","Invasion: Not obvious","Necrosis: Negative","Grade: Well","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303052/GSM303052.txt.gz","21619"
"GSM303053","Patient 058 with adenocarcinoma","GSM303053","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD058","Position in Figure 1 (L to R): 121","Age: 47","Sex: M","Histology: AD","Smoking (BI): 800","pTNM: T1N0M0","pStage: IA","Status: Dead","Survival (days): 2050","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Wt","K-ras Status: Mut","p53 Status: Mut","Gefitinib treatment: Y","Position in Figure 2 (L to R): 26","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Focal","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303053/GSM303053.txt.gz","21619"
"GSM303054","Patient 059 with adenocarcinoma","GSM303054","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD059","Position in Figure 1 (L to R): 146","Age: 74","Sex: M","Histology: AD","Smoking (BI): 1060","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2072","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 22","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303054/GSM303054.txt.gz","21619"
"GSM303055","Patient 060 with adenocarcinoma","GSM303055","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD060","Position in Figure 1 (L to R): 148","Age: 56","Sex: M","Histology: AD","Smoking (BI): 1260","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 440","Evidence of relapse: Y","Site of relapse: LN (neck)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 34","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303055/GSM303055.txt.gz","21619"
"GSM303056","Patient 061 with adenocarcinoma","GSM303056","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD061","Position in Figure 1 (L to R): 128","Age: 69","Sex: M","Histology: AD","Smoking (BI): 675","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2525","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 4","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303056/GSM303056.txt.gz","21619"
"GSM303057","Patient 062 with adenocarcinoma","GSM303057","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD062","Position in Figure 1 (L to R): 111","Age: 68","Sex: M","Histology: AD","Smoking (BI): 570","pTNM: T1N1M0","pStage: IIA","Status: Dead","Survival (days): 482","Evidence of relapse: Y","Site of relapse: Liver","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 10","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303057/GSM303057.txt.gz","21619"
"GSM303058","Patient 063 with adenocarcinoma","GSM303058","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD063","Position in Figure 1 (L to R): 126","Age: 41","Sex: M","Histology: AD","Smoking (BI): 60","pTNM: T1N0M0","pStage: IA","Status: Dead","Survival (days): 1164","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 30","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303058/GSM303058.txt.gz","21619"
"GSM303059","Patient 064 with adenocarcinoma","GSM303059","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD064","Position in Figure 1 (L to R): 123","Age: 55","Sex: M","Histology: AD","Smoking (BI): 1440","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2533","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 3","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303059/GSM303059.txt.gz","21619"
"GSM303060","Patient 065 with adenocarcinoma","GSM303060","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD065","Position in Figure 1 (L to R): 125","Age: 60","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2528","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 29","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Focal","Grade: Moderately","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303060/GSM303060.txt.gz","21619"
"GSM303061","Patient 066 with adenocarcinoma","GSM303061","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD066","Position in Figure 1 (L to R): 135","Age: 66","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2353","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 77","Expression profile-based classification: TRU-b","Invasion: Definite but focal","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303061/GSM303061.txt.gz","21619"
"GSM303062","Patient 067 with adenocarcinoma","GSM303062","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD067","Position in Figure 1 (L to R): 143","Age: 42","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2507","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 76","Expression profile-based classification: TRU-b","Invasion: Not obvious","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303062/GSM303062.txt.gz","21619"
"GSM303063","Patient 068 with adenocarcinoma","GSM303063","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD068","Position in Figure 1 (L to R): 116","Age: 56","Sex: M","Histology: AD","Smoking (BI): 720","pTNM: T3N0M0","pStage: IIB","Status: Alive","Survival (days): 2519","Evidence of relapse: Y","Site of relapse: PM?bone","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment: Y","Position in Figure 2 (L to R): 27","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303063/GSM303063.txt.gz","21619"
"GSM303064","Patient 069 with adenocarcinoma","GSM303064","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD069","Position in Figure 1 (L to R): 120","Age: 50","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2521","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment: Y","Position in Figure 2 (L to R): 25","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Focal","Grade: Well","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303064/GSM303064.txt.gz","21619"
"GSM303065","Patient 070 with adenocarcinoma","GSM303065","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD070","Position in Figure 1 (L to R): 145","Age: 70","Sex: F","Histology: AD","Smoking (BI): 400","pTNM: T1N2M0","pStage: IIIA","Status: Dead","Survival (days): 1501","Evidence of relapse: Y","Site of relapse: Bone","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 88","Expression profile-based classification: TRU-b","Invasion: Definite","Necrosis: Negative","Grade: Well","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303065/GSM303065.txt.gz","21619"
"GSM303066","Patient 071 with adenocarcinoma","GSM303066","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD071","Position in Figure 1 (L to R): 144","Age: 61","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2260","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 87","Expression profile-based classification: TRU-b","Invasion: Negative","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303066/GSM303066.txt.gz","21619"
"GSM303067","Patient 072 with adenocarcinoma","GSM303067","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD072","Position in Figure 1 (L to R): 93","Age: 63","Sex: M","Histology: AD","Smoking (BI): 900","pTNM: T2N2M0","pStage: IIIA","Status: Alive","Survival (days): 2339","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Mut","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 40","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Focal","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303067/GSM303067.txt.gz","21619"
"GSM303068","Patient 073 with adenocarcinoma","GSM303068","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD073","Position in Figure 1 (L to R): 64","Age: 60","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 1229","Evidence of relapse: Y","Site of relapse: local rec","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 52","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Focal","Grade: Poorly","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303068/GSM303068.txt.gz","21619"
"GSM303069","Patient 074 with adenocarcinoma","GSM303069","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD074","Position in Figure 1 (L to R): 108","Age: 58","Sex: M","Histology: AD","Smoking (BI): 690","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2341","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Mut","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 24","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303069/GSM303069.txt.gz","21619"
"GSM303070","Patient 075 with adenocarcinoma","GSM303070","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD075","Position in Figure 1 (L to R): 33","Age: 60","Sex: M","Histology: AD","Smoking (BI): 1200","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 777","Evidence of relapse: Y","Site of relapse: Local rec.","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 14","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303070/GSM303070.txt.gz","21619"
"GSM303071","Patient 076 with adenocarcinoma","GSM303071","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD076","Position in Figure 1 (L to R): 60","Age: 65","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Dead","Survival (days): 1333","Evidence of relapse: Y","Site of relapse: Local rec.,Brain","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 39","Expression profile-based classification: TRU-a","Invasion: Definite but focal","Necrosis: Negative","Grade: Moderately","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303071/GSM303071.txt.gz","21619"
"GSM303072","Patient 077 with adenocarcinoma","GSM303072","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD077","Position in Figure 1 (L to R): 84","Age: 60","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2348","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 38","Expression profile-based classification: TRU-a","Invasion: Definite but focal","Necrosis: Negative","Grade: Well","BAC features: +","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303072/GSM303072.txt.gz","21619"
"GSM303073","Patient 078 with adenocarcinoma","GSM303073","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD078","Position in Figure 1 (L to R): 39","Age: 82","Sex: M","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 1008","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 13","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303073/GSM303073.txt.gz","21619"
"GSM303074","Patient 079 with adenocarcinoma","GSM303074","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD079","Position in Figure 1 (L to R): 109","Age: 67","Sex: M","Histology: AD","Smoking (BI): 900","pTNM: T3N0M0","pStage: IIB","Status: Dead","Survival (days): 1201","Evidence of relapse: Y","Site of relapse: Bone","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 21","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303074/GSM303074.txt.gz","21619"
"GSM303075","Patient 080 with adenocarcinoma","GSM303075","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD080","Position in Figure 1 (L to R): 80","Age: 67","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 1956","Evidence of relapse: N","Site of relapse:","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 47","Expression profile-based classification: TRU-a","Invasion: Definite but focal","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303075/GSM303075.txt.gz","21619"
"GSM303076","Patient 081 with adenocarcinoma","GSM303076","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD081","Position in Figure 1 (L to R): 147","Age: 60","Sex: F","Histology: AD","Smoking (BI): 180","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 749","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 33","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303076/GSM303076.txt.gz","21619"
"GSM303077","Patient 082 with adenocarcinoma","GSM303077","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD082","Position in Figure 1 (L to R): 107","Age: 66","Sex: M","Histology: AD","Smoking (BI): 800","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2335","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 23","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303077/GSM303077.txt.gz","21619"
"GSM303078","Patient 083 with adenocarcinoma","GSM303078","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD083","Position in Figure 1 (L to R): 134","Age: 73","Sex: M","Histology: AD","Smoking (BI): 900","pTNM: T1N1M0","pStage: IIA","Status: Dead","Survival (days): 860","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 86","Expression profile-based classification: TRU-b","Invasion: Definite but focal","Necrosis: Focal","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303078/GSM303078.txt.gz","21619"
"GSM303079","Patient 084 with adenocarcinoma","GSM303079","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD084","Position in Figure 1 (L to R): 49","Age: 74","Sex: M","Histology: AD","Smoking (BI): 1160","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 186","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Mut","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 8","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303079/GSM303079.txt.gz","21619"
"GSM303080","Patient 085 with adenocarcinoma","GSM303080","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD085","Position in Figure 1 (L to R): 46","Age: 56","Sex: M","Histology: AD","Smoking (BI): 720","pTNM: T3N0M0","pStage: IIB","Status: Alive","Survival (days): 2342","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 17","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303080/GSM303080.txt.gz","21619"
"GSM303081","Patient 086 with adenocarcinoma","GSM303081","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD086","Position in Figure 1 (L to R): 79","Age: 49","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T1N2M0","pStage: IIIA","Status: Dead","Survival (days): 1074","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Mut","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 50","Expression profile-based classification: TRU-a","Invasion: Definite","Necrosis: Negative","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303081/GSM303081.txt.gz","21619"
"GSM303082","Patient 087 with adenocarcinoma","GSM303082","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD087","Position in Figure 1 (L to R): 44","Age: 60","Sex: F","Histology: AD","Smoking (BI): 0","pTNM: T2N1M0","pStage: IIB","Status: Dead","Survival (days): 867","Evidence of relapse: Y","Site of relapse: PM, Liver","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 35","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Moderately","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303082/GSM303082.txt.gz","21619"
"GSM303083","Patient 088 with adenocarcinoma","GSM303083","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD088","Position in Figure 1 (L to R): 41","Age: 53","Sex: M","Histology: AD","Smoking (BI): 1320","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 304","Evidence of relapse: Y","Site of relapse: LN (neck)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R): 16","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Positive","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303083/GSM303083.txt.gz","21619"
"GSM303084","Patient 089 with adenocarcinoma","GSM303084","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD089","Position in Figure 1 (L to R): 5","Age: 51","Sex: M","Histology: AD","Smoking (BI): 56","pTNM: T1N0M0","pStage: IA","Status: Dead","Survival (days): 906","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 15","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303084/GSM303084.txt.gz","21619"
"GSM303085","Patient 090 with adenocarcinoma","GSM303085","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AD090","Position in Figure 1 (L to R): 110","Age: 74","Sex: M","Histology: AD","Smoking (BI): 800","pTNM: T1N0M0","pStage: IA","Status: Dead","Survival (days): 477","Evidence of relapse: Y","Site of relapse: Local rec.","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R): 9","Expression profile-based classification: Non-TRU","Invasion: Definite","Necrosis: Negative","Grade: Poorly","BAC features: -","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303085/GSM303085.txt.gz","21619"
"GSM303086","Patient 001 with adenocarcinoma AS001","GSM303086","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AS001","Position in Figure 1 (L to R): 130","Age: 71","Sex: M","Histology: AS","Smoking (BI): 600","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 1425","Evidence of relapse: Y","Site of relapse: Bone","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303086/GSM303086.txt.gz","21619"
"GSM303087","Patient 002 with adenocarcinoma AS002","GSM303087","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AS002","Position in Figure 1 (L to R): 11","Age: 71","Sex: M","Histology: AS","Smoking (BI): 700","pTNM: T3N1M0","pStage: IIIA","Status: Dead","Survival (days): 309","Evidence of relapse: Y","Site of relapse: Skin","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303087/GSM303087.txt.gz","21619"
"GSM303088","Patient 003 with adenocarcinoma AS003","GSM303088","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AS003","Position in Figure 1 (L to R): 141","Age: 52","Sex: M","Histology: AS","Smoking (BI): 440","pTNM: T1N0M0","pStage: IA","Status: Dead","Survival (days): 2428","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment: Y","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303088/GSM303088.txt.gz","21619"
"GSM303089","Patient 004 with adenocarcinoma AS004","GSM303089","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: AS004","Position in Figure 1 (L to R): 101","Age: 73","Sex: M","Histology: AS","Smoking (BI): 1200","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 3066","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303089/GSM303089.txt.gz","21619"
"GSM303090","Patient 001 with large-cell carcinoma","GSM303090","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA001","Position in Figure 1 (L to R): 99","Age: 68","Sex: M","Histology: LA","Smoking (BI): 1150","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 3263","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303090/GSM303090.txt.gz","21619"
"GSM303091","Patient 002 with large-cell carcinoma","GSM303091","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA002","Position in Figure 1 (L to R): 53","Age: 69","Sex: M","Histology: LA","Smoking (BI): 1020","pTNM: T1N1M0","pStage: IIA","Status: Alive","Survival (days): 3238","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303091/GSM303091.txt.gz","21619"
"GSM303092","Patient 003 with large-cell carcinoma","GSM303092","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA003","Position in Figure 1 (L to R): 50","Age: 76","Sex: M","Histology: LA","Smoking (BI): 825","pTNM: T2N1M0","pStage: IIB","Status: Dead","Survival (days): 75","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303092/GSM303092.txt.gz","21619"
"GSM303093","Patient 004 with large-cell carcinoma","GSM303093","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA004","Position in Figure 1 (L to R): 40","Age: 63","Sex: M","Histology: LA","Smoking (BI): 1290","pTNM: T3N0M0","pStage: IIB","Status: Dead","Survival (days): 198","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303093/GSM303093.txt.gz","21619"
"GSM303094","Patient 005 with large-cell carcinoma","GSM303094","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA005","Position in Figure 1 (L to R): 86","Age: 46","Sex: F","Histology: LA","Smoking (BI): 0","pTNM: T2N3M0","pStage: IIIB","Status: Dead","Survival (days): 660","Evidence of relapse: Y","Site of relapse: LN (mediastinal)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303094/GSM303094.txt.gz","21619"
"GSM303095","Patient 006 with large-cell carcinoma","GSM303095","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA006","Position in Figure 1 (L to R): 34","Age: 63","Sex: M","Histology: LA","Smoking (BI): 1350","pTNM: T2N3M0","pStage: IIIB","Status: Dead","Survival (days): 422","Evidence of relapse: Y","Site of relapse: LN (mediastinal)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303095/GSM303095.txt.gz","21619"
"GSM303096","Patient 007 with large-cell carcinoma","GSM303096","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA007","Position in Figure 1 (L to R): 35","Age: 52","Sex: M","Histology: LA","Smoking (BI): 640","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2713","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303096/GSM303096.txt.gz","21619"
"GSM303097","Patient 008 with large-cell carcinoma","GSM303097","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA008","Position in Figure 1 (L to R): 38","Age: 64","Sex: F","Histology: LA","Smoking (BI): 0","pTNM: T3N0M0","pStage: IIB","Status: Dead","Survival (days): 297","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303097/GSM303097.txt.gz","21619"
"GSM303098","Patient 009 with large-cell carcinoma","GSM303098","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA009","Position in Figure 1 (L to R): 36","Age: 68","Sex: M","Histology: LA","Smoking (BI): 1325","pTNM: T3N0M0","pStage: IIB","Status: Dead","Survival (days): 127","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303098/GSM303098.txt.gz","21619"
"GSM303099","Patient 010 with large-cell carcinoma","GSM303099","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA010","Position in Figure 1 (L to R): 37","Age: 41","Sex: M","Histology: LA","Smoking (BI): 690","pTNM: T3N0M0","pStage: IIB","Status: Alive","Survival (days): 2712","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303099/GSM303099.txt.gz","21619"
"GSM303100","Patient 011 with large-cell carcinoma","GSM303100","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA011","Position in Figure 1 (L to R): 48","Age: 43","Sex: M","Histology: LA","Smoking (BI): 460","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2681","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303100/GSM303100.txt.gz","21619"
"GSM303101","Patient 012 with large-cell carcinoma","GSM303101","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA012","Position in Figure 1 (L to R): 47","Age: 60","Sex: M","Histology: LA","Smoking (BI): 1200","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 134","Evidence of relapse: Y","Site of relapse: PM, Local rec.","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303101/GSM303101.txt.gz","21619"
"GSM303102","Patient 013 with large-cell carcinoma","GSM303102","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA013","Position in Figure 1 (L to R): 88","Age: 72","Sex: M","Histology: LA","Smoking (BI): 400","pTNM: T2N1M0","pStage: IIB","Status: Dead","Survival (days): 1454","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303102/GSM303102.txt.gz","21619"
"GSM303103","Patient 014 with large-cell carcinoma","GSM303103","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA014","Position in Figure 1 (L to R): 105","Age: 56","Sex: F","Histology: LA","Smoking (BI): 0","pTNM: T2N1M0","pStage: IIB","Status: Alive","Survival (days): 2688","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Mut","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303103/GSM303103.txt.gz","21619"
"GSM303104","Patient 015 with large-cell carcinoma","GSM303104","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA015","Position in Figure 1 (L to R): 45","Age: 52","Sex: M","Histology: LA","Smoking (BI): 1750","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2521","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303104/GSM303104.txt.gz","21619"
"GSM303105","Patient 016 with large-cell carcinoma","GSM303105","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA016","Position in Figure 1 (L to R): 132","Age: 46","Sex: M","Histology: LA","Smoking (BI): 720","pTNM: T1N2M0","pStage: IIIA","Status: Dead","Survival (days): 374","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Mut","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303105/GSM303105.txt.gz","21619"
"GSM303106","Patient 017 with large-cell carcinoma","GSM303106","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA017","Position in Figure 1 (L to R): 42","Age: 71","Sex: M","Histology: LA","Smoking (BI): 660","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2634","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303106/GSM303106.txt.gz","21619"
"GSM303107","Patient 018 with large-cell carcinoma","GSM303107","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LA018","Position in Figure 1 (L to R): 52","Age: 77","Sex: M","Histology: LA","Smoking (BI): 400","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2353","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303107/GSM303107.txt.gz","21619"
"GSM303108","Patient 001 with large cell neuroendocrine carcinoma","GSM303108","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LCNEC001","Position in Figure 1 (L to R): 97","Age: 71","Sex: M","Histology: LCNEC","Smoking (BI): 980","pTNM: T4N0M0","pStage: IIIB","Status: Dead","Survival (days): 229","Evidence of relapse: Y","Site of relapse: Brain","EGFR status: Wt","K-ras Status: Mut","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303108/GSM303108.txt.gz","21619"
"GSM303109","Patient 002 with large cell neuroendocrine carcinoma","GSM303109","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: LCNEC002","Position in Figure 1 (L to R): 43","Age: 69","Sex: M","Histology: LCNEC","Smoking (BI): 940","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 790","Evidence of relapse: Y","Site of relapse: LN (mediastinal)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303109/GSM303109.txt.gz","21619"
"GSM303110","Patient 001 with squamous cell carcinoma","GSM303110","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ001","Position in Figure 1 (L to R): 55","Age: 74","Sex: F","Histology: SQ","Smoking (BI): 0","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 3429","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303110/GSM303110.txt.gz","21619"
"GSM303111","Patient 002 with squamous cell carcinoma","GSM303111","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ002","Position in Figure 1 (L to R): 1","Age: 61","Sex: M","Histology: SQ","Smoking (BI): 1050","pTNM: T3N0M0","pStage: IIB","Status: Alive","Survival (days): 3596","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303111/GSM303111.txt.gz","21619"
"GSM303112","Patient 003 with squamous cell carcinoma","GSM303112","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ003","Position in Figure 1 (L to R): 29","Age: 63","Sex: M","Histology: SQ","Smoking (BI): 1610","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 220","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303112/GSM303112.txt.gz","21619"
"GSM303113","Patient 004 with squamous cell carcinoma","GSM303113","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ004","Position in Figure 1 (L to R): 7","Age: 55","Sex: M","Histology: SQ","Smoking (BI): 2800","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 1565","Evidence of relapse: Y","Site of relapse: PM, brain","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303113/GSM303113.txt.gz","21619"
"GSM303114","Patient 005 with squamous cell carcinoma","GSM303114","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ005","Position in Figure 1 (L to R): 6","Age: 75","Sex: M","Histology: SQ","Smoking (BI): 1920","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 2196","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303114/GSM303114.txt.gz","21619"
"GSM303115","Patient 006 with squamous cell carcinoma","GSM303115","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ006","Position in Figure 1 (L to R): 28","Age: 65","Sex: M","Histology: SQ","Smoking (BI): 1350","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2818","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303115/GSM303115.txt.gz","21619"
"GSM303116","Patient 007 with squamous cell carcinoma","GSM303116","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ007","Position in Figure 1 (L to R): 18","Age: 61","Sex: M","Histology: SQ","Smoking (BI): 800","pTNM: T2N1M0","pStage: IIB","Status: Alive","Survival (days): 3282","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303116/GSM303116.txt.gz","21619"
"GSM303117","Patient 008 with squamous cell carcinoma","GSM303117","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ008","Position in Figure 1 (L to R): 27","Age: 58","Sex: M","Histology: SQ","Smoking (BI): 760","pTNM: T2N2M0","pStage: IIIA","Status: Alive","Survival (days): 3238","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303117/GSM303117.txt.gz","21619"
"GSM303118","Patient 009 with squamous cell carcinoma","GSM303118","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ009","Position in Figure 1 (L to R): 12","Age: 75","Sex: M","Histology: SQ","Smoking (BI): 275","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 764","Evidence of relapse: Y","Site of relapse: Liver","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303118/GSM303118.txt.gz","21619"
"GSM303119","Patient 010 with squamous cell carcinoma","GSM303119","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ010","Position in Figure 1 (L to R): 32","Age: 62","Sex: M","Histology: SQ","Smoking (BI): 1470","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2998","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303119/GSM303119.txt.gz","21619"
"GSM303120","Patient 011 with squamous cell carcinoma","GSM303120","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ011","Position in Figure 1 (L to R): 54","Age: 57","Sex: M","Histology: SQ","Smoking (BI): 3360","pTNM: T3N1M0","pStage: IIIA","Status: Dead","Survival (days): 1554","Evidence of relapse: Y","Site of relapse: LN (mediastinal)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303120/GSM303120.txt.gz","21619"
"GSM303121","Patient 012 with squamous cell carcinoma","GSM303121","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ012","Position in Figure 1 (L to R): 17","Age: 59","Sex: M","Histology: SQ","Smoking (BI): 1050","pTNM: T3N1M0","pStage: IIIA","Status: Dead","Survival (days): 232","Evidence of relapse: Y","Site of relapse: Bone","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303121/GSM303121.txt.gz","21619"
"GSM303122","Patient 013 with squamous cell carcinoma","GSM303122","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ013","Position in Figure 1 (L to R): 13","Age: 63","Sex: M","Histology: SQ","Smoking (BI): 1680","pTNM: T2N1M0","pStage: IIB","Status: Alive","Survival (days): 2823","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303122/GSM303122.txt.gz","21619"
"GSM303123","Patient 014 with squamous cell carcinoma","GSM303123","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ014","Position in Figure 1 (L to R): 19","Age: 58","Sex: M","Histology: SQ","Smoking (BI): 2960","pTNM: T2N1M0","pStage: IIB","Status: Alive","Survival (days): 2888","Evidence of relapse: Y","Site of relapse: Local rec","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303123/GSM303123.txt.gz","21619"
"GSM303124","Patient 015 with squamous cell carcinoma","GSM303124","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ015","Position in Figure 1 (L to R): 31","Age: 67","Sex: M","Histology: SQ","Smoking (BI): 740","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 933","Evidence of relapse: Y","Site of relapse: LN (mediastinal)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303124/GSM303124.txt.gz","21619"
"GSM303125","Patient 016 with squamous cell carcinoma","GSM303125","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ016","Position in Figure 1 (L to R): 30","Age: 63","Sex: M","Histology: SQ","Smoking (BI): 860","pTNM: T4N1M0","pStage: IIIB","Status: Dead","Survival (days): 445","Evidence of relapse: Y","Site of relapse: Bone, liver","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303125/GSM303125.txt.gz","21619"
"GSM303126","Patient 017 with squamous cell carcinoma","GSM303126","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ017","Position in Figure 1 (L to R): 14","Age: 55","Sex: M","Histology: SQ","Smoking (BI): 1800","pTNM: T3N1M0","pStage: IIIA","Status: Alive","Survival (days): 2910","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303126/GSM303126.txt.gz","21619"
"GSM303127","Patient 018 with squamous cell carcinoma","GSM303127","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ018","Position in Figure 1 (L to R): 15","Age: 58","Sex: M","Histology: SQ","Smoking (BI): 1600","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2886","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303127/GSM303127.txt.gz","21619"
"GSM303128","Patient 019 with squamous cell carcinoma","GSM303128","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ019","Position in Figure 1 (L to R): 16","Age: 47","Sex: M","Histology: SQ","Smoking (BI): 1080","pTNM: T1N0M0","pStage: IA","Status: Alive","Survival (days): 2718","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303128/GSM303128.txt.gz","21619"
"GSM303129","Patient 020 with squamous cell carcinoma","GSM303129","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ020","Position in Figure 1 (L to R): 26","Age: 46","Sex: F","Histology: SQ","Smoking (BI): 650","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 888","Evidence of relapse: Y","Site of relapse: Kidney","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303129/GSM303129.txt.gz","21619"
"GSM303130","Patient 021 with squamous cell carcinoma","GSM303130","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ021","Position in Figure 1 (L to R): 10","Age: 70","Sex: M","Histology: SQ","Smoking (BI): 1500","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2705","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303130/GSM303130.txt.gz","21619"
"GSM303131","Patient 022 with squamous cell carcinoma","GSM303131","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ022","Position in Figure 1 (L to R): 3","Age: 72","Sex: M","Histology: SQ","Smoking (BI): 940","pTNM: T1N0M0","pStage: IA","Status: Dead","Survival (days): 2546","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303131/GSM303131.txt.gz","21619"
"GSM303132","Patient 023 with squamous cell carcinoma","GSM303132","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ023","Position in Figure 1 (L to R): 20","Age: 64","Sex: M","Histology: SQ","Smoking (BI): 600","pTNM: T3N0M0","pStage: IIB","Status: Dead","Survival (days): 1463","Evidence of relapse: Y","Site of relapse: Local rec","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303132/GSM303132.txt.gz","21619"
"GSM303133","Patient 024 with squamous cell carcinoma","GSM303133","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ024","Position in Figure 1 (L to R): 21","Age: 77","Sex: M","Histology: SQ","Smoking (BI): 940","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 139","Evidence of relapse: Y","Site of relapse: Brain, local rec.","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303133/GSM303133.txt.gz","21619"
"GSM303134","Patient 025 with squamous cell carcinoma","GSM303134","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ025","Position in Figure 1 (L to R): 87","Age: 75","Sex: M","Histology: SQ","Smoking (BI): 940","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2513","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303134/GSM303134.txt.gz","21619"
"GSM303135","Patient 026 with squamous cell carcinoma","GSM303135","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ026","Position in Figure 1 (L to R): 8","Age: 69","Sex: M","Histology: SQ","Smoking (BI): 2700","pTNM: T4N1M0","pStage: IIIB","Status: Dead","Survival (days): 2528","Evidence of relapse: Y","Site of relapse: PM","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303135/GSM303135.txt.gz","21619"
"GSM303136","Patient 027 with squamous cell carcinoma","GSM303136","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ027","Position in Figure 1 (L to R): 9","Age: 72","Sex: M","Histology: SQ","Smoking (BI): 4050","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 25","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303136/GSM303136.txt.gz","21619"
"GSM303137","Patient 028 with squamous cell carcinoma","GSM303137","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ028","Position in Figure 1 (L to R): 23","Age: 68","Sex: M","Histology: SQ","Smoking (BI): 960","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 25","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303137/GSM303137.txt.gz","21619"
"GSM303138","Patient 029 with squamous cell carcinoma","GSM303138","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ029","Position in Figure 1 (L to R): 124","Age: 72","Sex: M","Histology: SQ","Smoking (BI): 1250","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2533","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303138/GSM303138.txt.gz","21619"
"GSM303139","Patient 030 with squamous cell carcinoma","GSM303139","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ030","Position in Figure 1 (L to R): 24","Age: 79","Sex: M","Histology: SQ","Smoking (BI): 780","pTNM: T2N0M0","pStage: IB","Status: Alive","Survival (days): 2358","Evidence of relapse: N","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303139/GSM303139.txt.gz","21619"
"GSM303140","Patient 031 with squamous cell carcinoma","GSM303140","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ031","Position in Figure 1 (L to R): 2","Age: 76","Sex: M","Histology: SQ","Smoking (BI): 1250","pTNM: T1N0M0","pStage: IA","Status: Dead","Survival (days): 288","Evidence of relapse: Unknown","Site of relapse:","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303140/GSM303140.txt.gz","21619"
"GSM303141","Patient 032 with squamous cell carcinoma","GSM303141","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ032","Position in Figure 1 (L to R): 4","Age: 73","Sex: M","Histology: SQ","Smoking (BI): 1060","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 1862","Evidence of relapse: Y","Site of relapse: Local rec","EGFR status: Wt","K-ras Status: Wt","p53 Status: Wt","Gefitinib treatment: Y","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303141/GSM303141.txt.gz","21619"
"GSM303142","Patient 033 with squamous cell carcinoma","GSM303142","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ033","Position in Figure 1 (L to R): 25","Age: 72","Sex: M","Histology: SQ","Smoking (BI): 1000","pTNM: T2N0M0","pStage: IB","Status: Dead","Survival (days): 683","Evidence of relapse: Y","Site of relapse: LN (mediastinal)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303142/GSM303142.txt.gz","21619"
"GSM303143","Patient 034 with squamous cell carcinoma","GSM303143","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ034","Position in Figure 1 (L to R): 115","Age: 56","Sex: M","Histology: SQ","Smoking (BI): 1440","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 683","Evidence of relapse: Y","Site of relapse: Kidney","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303143/GSM303143.txt.gz","21619"
"GSM303144","Patient 035 with squamous cell carcinoma","GSM303144","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SQ035","Position in Figure 1 (L to R): 22","Age: 73","Sex: M","Histology: SQ","Smoking (BI): 1060","pTNM: T2N2M0","pStage: IIIA","Status: Dead","Survival (days): 795","Evidence of relapse: Y","Site of relapse: LN (mediastinal)","EGFR status: Wt","K-ras Status: Wt","p53 Status: Mut","Gefitinib treatment:","Position in Figure 2 (L to R):","Expression profile-based classification:","Invasion:","Necrosis:","Grade:","BAC features:","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303144/GSM303144.txt.gz","21619"
"GSM303145","Patient 01 with small cell lung cancer","GSM303145","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SCLC01","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: SCLC","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy6","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303145/GSM303145.txt.gz","21619"
"GSM303146","Patient 02 with small cell lung cancer","GSM303146","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SCLC02","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: SCLC","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy7","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303146/GSM303146.txt.gz","21619"
"GSM303147","Patient 03 with small cell lung cancer","GSM303147","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SCLC03","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: SCLC","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy8","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303147/GSM303147.txt.gz","21619"
"GSM303148","Patient 04 with small cell lung cancer","GSM303148","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SCLC04","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: SCLC","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy9","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303148/GSM303148.txt.gz","21619"
"GSM303149","Patient 05 with small cell lung cancer","GSM303149","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SCLC05","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: SCLC","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy10","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303149/GSM303149.txt.gz","21619"
"GSM303150","Patient 06 with small cell lung cancer","GSM303150","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SCLC06","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: SCLC","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy11","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303150/GSM303150.txt.gz","21619"
"GSM303151","Patient 07 with small cell lung cancer","GSM303151","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SCLC07","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: SCLC","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy12","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303151/GSM303151.txt.gz","21619"
"GSM303152","Patient 08 with small cell lung cancer","GSM303152","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SCLC08","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: SCLC","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy13","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303152/GSM303152.txt.gz","21619"
"GSM303153","Patient 09 with small cell lung cancer","GSM303153","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Primary lung tumor","Homo sapiens","Annotation: SCLC09","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: SCLC","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy14","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303153/GSM303153.txt.gz","21619"
"GSM303154","Mixture of normal tissue from 5 different patients, mixture no.1","GSM303154","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Normal lung tissue","Homo sapiens","Annotation: Normal01","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: Normal lung tissue","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303154/GSM303154.txt.gz","21619"
"GSM303155","Mixture of normal tissue from 5 different patients, mixture no.2","GSM303155","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Normal lung tissue","Homo sapiens","Annotation: Normal02","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: Normal lung tissue","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303155/GSM303155.txt.gz","21619"
"GSM303156","Mixture of normal tissue from 5 different patients, mixture no.3","GSM303156","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Normal lung tissue","Homo sapiens","Annotation: Normal03","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: Normal lung tissue","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303156/GSM303156.txt.gz","21619"
"GSM303157","Mixture of normal tissue from 5 different patients, mixture no.4","GSM303157","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Normal lung tissue","Homo sapiens","Annotation: Normal04","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: Normal lung tissue","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303157/GSM303157.txt.gz","21619"
"GSM303158","Mixture of normal tissue from 5 different patients, mixture no.5","GSM303158","Public on Apr 01 2009","Jul 02 2008","Jul 02 2008","RNA","2","Normal lung tissue","Homo sapiens","Annotation: Normal05","Position in Figure 1 (L to R): NA","Age: NA","Sex: NA","Histology: Normal lung tissue","Smoking (BI): NA","pTNM: NA","pStage: NA","Status: NA","Survival (days): NA","Evidence of relapse: NA","Site of relapse: NA","EGFR status: NA","K-ras Status: NA","p53 Status: NA","Gefitinib treatment: NA","Position in Figure 2 (L to R): NA","Expression profile-based classification: NA","Invasion: NA","Necrosis: NA","Grade: NA","BAC features: NA","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy5","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Total RNA from 20 lung cell lines representing all major histological types of lung cancers, labeled with Cyanine-3 (green).","Homo sapiens","n/a","total RNA","Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), followed by treatment with DNase I. Double-stranded cDNA was synthesized from 250 ng of total RNA using MMLV-RT and poly dT primer incorporating the T7 promoter.","Cy3","cRNA was generated and labeled with Cy3 or Cy5 (CyDye, Amersham Pharmacia Biotech, Piscataway, NJ) using the Low RNA Fluorescent Linear Amplification kit (Agilent Technologies, Palo Alto, CA).","9606","Cy5-sample cRNA and Cy3-common reference cRNA were hybridized to a custom Agilent oligonucleotide microarray, containing a total of 21,619 spots corresponding to 18,175 unique genes, followed by confocal laser scanning (Agilent Technologies).","Scanned on an Agilent G2565AA scanner.","Images were quantified using Agilent Feature Extraction Software (version A.7.5).","n/a","LOWESS normalized, background subtracted VALUE data obtained from log10 of processed Red signal/processed Green signal. Agilent software was used.","GPL7015","Takahashi,,Takashi","Division of Molecular Carcinogenesis","Graduate School of Medicine","Nagoya University","65 Tsurumaicho, Showa-ku","Nagoya","Aichi","466-8550","Japan","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM303nnn/GSM303158/GSM303158.txt.gz","21619"
